Business Context and Reporting Period
This Form 8-K is filed by TRxADE HEALTH, Inc. (trading symbol: MEDS) on November 29, 2022. The report addresses regulatory compliance issues regarding the company's continued listing on The Nasdaq Capital Market. The filing was signed by Suren Ajjarapu, Chief Executive Officer, on December 1, 2022.
Key Financial Metrics and Listing Status
The filing does not provide specific revenue, profit, cash flow, or debt figures. Instead, it details two critical listing deficiencies:
- Minimum Bid Price: The company failed to maintain the required minimum bid price of $1.00 per share for 30 consecutive business days (October 14, 2022, to November 28, 2022).
- Stockholders' Equity: The company is not in compliance with the minimum stockholders' equity requirement of $2,500,000.
Material Changes and Compliance Deadlines
The company received a Notification Letter from Nasdaq regarding the bid price deficiency. Key timelines and requirements include:
- Bid Price Compliance: The company has 180 calendar days (until May 29, 2023) to regain compliance. This requires a closing bid price of at least $1.00 per share for 10 consecutive business days.
- Equity Compliance: The company must complete certain transactions by January 25, 2023, to evidence compliance with the stockholders' equity rule. This includes a previously completed public sale of $1.75 million of common stock (or pre-funded warrants) on October 7, 2022.
- Delisting Risk: Failure to regain compliance by the deadlines may result in delisting, though the company may appeal to a Hearings Panel or seek a second 180-day compliance period if initial listing criteria are met.
Management Commentary and Risks
Management intends to monitor the closing bid price and may consider implementing options, such as a reverse stock split, to regain compliance. The primary risk identified is the potential delisting of the company's common stock if the bid price and equity requirements are not met within the specified grace periods. The filing notes that the Notification Letter does not impact the current listing status immediately.
Investor Verification Checklist
- Verify the current closing bid price of MEDS stock to assess progress toward the $1.00 threshold.
- Confirm the status of the transactions required to meet the $2,500,000 stockholders' equity requirement by the January 25, 2023 deadline.
- Monitor for any announcements regarding a reverse stock split or other capital structure changes.
- Review subsequent filings to ensure the company has formally notified Nasdaq of its intention to cure deficiencies if the first compliance period is missed.